Screener
MaxCyte MXCT Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 79.2%-0.6pp | 80.5%-0.4pp | 81.2%-0.5pp | 80%-6.0pp | 79.8%-8.6pp | |
| Operating margin | -134.6%+15.0pp | -141.8%-5.9pp | -157.1%-24.6pp | -155.6%-53.9pp | -149.6%-47.7pp | |
| Net margin | -114.8%+10.5pp | -121.2%-10.2pp | -135.1%-28.9pp | -132.6%-54.2pp | -125.2%-47.3pp | |
| Returns | ||||||
| Return on equity | -20.4%+1.3pp | -21.3%-1.7pp | -23.6%-4.9pp | -23.2%-7.2pp | -21.7%-6.4pp | |
| Return on invested capital | -23.5%+3.4pp | -25%-0.5pp | -28.4%-2.8pp | -28.2%-4.7pp | -27%-4.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.2×0.0× | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | |
| Liquidity | ||||||
| Current ratio | 12.3×-0.1× | 12×-0.2× | 8.3×-2.6× | 7.7×-2.1× | 12.4×-1.9× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $1.49-17.1% | $1.57-16.5% | $1.61-18.1% | $1.69-16.7% | $1.79-15.2% | |
| Valuation | ||||||
| Market capitalization | $135.2M-9.4% | $75.07M-74.1% | $165.34M-62.3% | $168.44M-58.6% | $235.5M-42.3% | |
| Price / sales | 4.4×+0.2× | 2.3×-5.4× | 5×-6.4× | 4.9×-4.0× | 6.6×-2.4× | |
| Price / book | 0.9×+0.1× | 0.4×-1.0× | 1×-1.2× | 0.9×-1.0× | 1.2×-0.6× |
FAQ
- What are MaxCyte's profit margins?
- MaxCyte (MXCT) runs a 79.2% gross margin and a -134.6% operating margin, with a -114.8% net margin.
- Where do MaxCyte's ratios come from?
- Every ratio is computed from MaxCyte's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
